Jiuzhou Pharma(603456.SH)

Last Updated 00:00:00
longbridge loading

The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

Zhitong·
SZ
301230
-1.55%
SZ
300347
-1.58%
HK
03347
-1.01%
Zhitong·
SZ
301230
-1.55%
SZ
300347
-1.58%
HK
03347
-1.01%

Jiuzhou Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 748 million yuan, a year-on-year increase of 18.51%

Zhitong·
SH
603456
-0.76%
Zhitong·
SH
603456
-0.76%

CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up

Zhitong·
SZ
000739
+2.56%
SH
603456
-0.76%
SH
603127
+1.17%
Zhitong·
SZ
000739
+2.56%
SH
603456
-0.76%
SH
603127
+1.17%

Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA

Zhitong·
SH
603456
-0.76%
Zhitong·
SH
603456
-0.76%

Cinda Securities: Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth points

Zhitong·
SH
603456
-0.76%
Zhitong·
SH
603456
-0.76%

28 stocks received buy ratings from brokerages, with Jiuzhou Pharma's target increase reaching 57.75%

Zhitong·
SZ
002891
-0.92%
SH
603456
-0.76%
Zhitong·
SZ
002891
-0.92%
SH
603456
-0.76%

The social security fund appears among the top ten circulating shareholders of three stocks, with a total holding market value of 282 million yuan

Zhitong·
SZ
000404
-5.11%
SH
603508
-0.89%
SH
603456
-0.76%
Zhitong·
SZ
000404
-5.11%
SH
603508
-0.89%
SH
603456
-0.76%

Jiuzhou Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 526 million yuan, an increase of 10.70%

Zhitong·
SH
603456
-0.76%
Zhitong·
SH
603456
-0.76%

Guotai Junan Securities: The overall CXO investment and financing is showing a warming trend, focusing on investment opportunities in the new molecular industrial chain

Zhitong·
SH
603456
-0.76%
SZ
300759
+1.29%
HK
03759
+0.83%
Zhitong·
SH
603456
-0.76%
SZ
300759
+1.29%
HK
03759
+0.83%

CRO/CMO concept experiences a volatile surge, ChemPartner hits the "20cm" limit up

Zhitong·
SH
603456
-0.76%
SZ
300347
-1.58%
HK
03347
-1.01%
Zhitong·
SH
603456
-0.76%
SZ
300347
-1.58%
HK
03347
-1.01%
© 2026 Longbridge｜Disclaimer